• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Officer Dadakis Alex

    6/11/25 5:15:11 PM ET
    $ULS
    Precision Instruments
    Health Care
    Get the next $ULS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Dadakis Alex

    (Last) (First) (Middle)
    C/O UL SOLUTIONS INC.
    333 PFINGSTEN RD

    (Street)
    NORTHBROOK IL 60062

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    UL Solutions Inc. [ ULS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    06/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 06/09/2025 A 29(2)(3) (4) (4) Class A Common Stock 29 $0 15,946(5) D
    Restricted Stock Units (1) 06/09/2025 A 9(2)(3) (6) (6) Class A Common Stock 9 $0 5,194(5) D
    Explanation of Responses:
    1. Each dividend equivalent right represents a contingent right to receive one share of the Issuer's Class A Common Stock.
    2. Represents accrual of dividend equivalent rights on restricted stock units held by the Reporting Person.
    3. The dividend equivalent rights have historically been reported as a separate security on Table II, but have been aggregated with the underlying restricted stock units in this Form 4 and will continue to be reported together with the underlying equity award in the future.
    4. The dividend equivalent rights accrued on restricted stock units held by the Reporting Person and vest proportionately with the restricted stock units to which they relate. The restricted stock units will vest in three equal installments on the first, second and third anniversaries of March 3, 2025.
    5. Includes restricted stock units and all dividend equivalent rights that have accrued on such restricted stock units to date.
    6. The dividend equivalent rights accrued on restricted stock units held by the Reporting Person and vest proportionately with the restricted stock units to which they relate. The restricted stock units will vest in three equal installments on the first, second and third anniversaries of April 1, 2025.
    Remarks:
    Executive Vice President, Chief Business Operations and Innovation Officer
    /s/ Ryan Robinson, Attorney-in-Fact 06/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ULS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ULS

    DatePrice TargetRatingAnalyst
    5/14/2025$71.00Buy → Neutral
    Citigroup
    10/7/2024$60.00Buy
    Citigroup
    7/12/2024$41.00 → $46.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $ULS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by UL Solutions Inc.

      SCHEDULE 13G/A - UL Solutions Inc. (0001901440) (Subject)

      6/6/25 12:06:11 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - UL Solutions Inc. (0001901440) (Filer)

      5/22/25 4:36:38 PM ET
      $ULS
      Precision Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by UL Solutions Inc.

      SCHEDULE 13G/A - UL Solutions Inc. (0001901440) (Subject)

      5/12/25 10:43:30 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by UL Solutions Inc.

      SC 13G/A - UL Solutions Inc. (0001901440) (Subject)

      11/13/24 12:26:41 PM ET
      $ULS
      Precision Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UL Solutions Inc.

      SC 13G/A - UL Solutions Inc. (0001901440) (Subject)

      11/12/24 5:49:12 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form SC 13G filed by UL Solutions Inc.

      SC 13G - UL Solutions Inc. (0001901440) (Subject)

      11/12/24 10:34:15 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Thaman Michael H

      4 - UL Solutions Inc. (0001901440) (Issuer)

      6/11/25 5:15:54 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form 4 filed by Director Dollive James P

      4 - UL Solutions Inc. (0001901440) (Issuer)

      6/11/25 5:15:51 PM ET
      $ULS
      Precision Instruments
      Health Care
    • SEC Form 4 filed by Director Susman Sally

      4 - UL Solutions Inc. (0001901440) (Issuer)

      6/11/25 5:15:47 PM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • UL Solutions to Attend Upcoming Investor Conferences

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced that senior management of the company will participate in the following investor conferences: William Blair 45th Annual Growth Stock Conference, June 3 Stifel 2025 Boston Cross Sector 1x1 Conference, June 4 and Baird 2025 Global Consumer, Technology & Services Conference, June 5. The company's presentation at the William Blair 45th Annual Growth Stock Conference, at 3:00 p.m. EDT (2:00 p.m. CDT) on June 3, will be broadcast live. The webcast can be accessed through the UL Solutions Investor Relations website at ir.ul.com. A replay of the webcast will be available on the website for 30 days a

      5/29/25 4:45:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Announces Quarterly Dividend

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced that its board of directors has declared a quarterly dividend of $0.13 per share. The dividend will be paid on June 9 to shareholders of record as of the close of business on May 30. About UL Solutions A global leader in applied safety science, UL Solutions Inc. (NYSE:ULS) transforms safety, security and sustainability challenges into opportunities for customers in more than 110 countries. UL Solutions delivers testing, inspection and certification services, together with software products and advisory offerings, that support our customers' product innovation and business growth. The UL Mark serves a

      5/20/25 6:32:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Launches Advanced Battery Testing Center in Europe

      The UL Solutions Europe Advanced Battery Laboratory in Aachen, Germany, provides testing, simulation and certification services addressing automotive and stationary battery research, safety and performance. UL Solutions Inc. (NYSE:ULS) today announced the opening of its Europe Advanced Battery Testing Laboratory in Aachen, Germany, which will test batteries used in electric vehicles (EVs) and large-scale energy storage systems, significantly expanding the company's battery technology testing capabilities and its European footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513936962/en/Guests celebrate the opening of the

      5/15/25 8:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UL Solutions Inc. downgraded by Citigroup with a new price target

      Citigroup downgraded UL Solutions Inc. from Buy to Neutral and set a new price target of $71.00

      5/14/25 8:58:56 AM ET
      $ULS
      Precision Instruments
      Health Care
    • Citigroup resumed coverage on UL Solutions Inc. with a new price target

      Citigroup resumed coverage of UL Solutions Inc. with a rating of Buy and set a new price target of $60.00

      10/7/24 8:45:25 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded UL Solutions Inc. from Outperform to Neutral and set a new price target of $46.00 from $41.00 previously

      7/12/24 7:43:51 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Financials

    Live finance-specific insights

    See more
    • UL Solutions Announces Quarterly Dividend

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced that its board of directors has declared a quarterly dividend of $0.13 per share. The dividend will be paid on June 9 to shareholders of record as of the close of business on May 30. About UL Solutions A global leader in applied safety science, UL Solutions Inc. (NYSE:ULS) transforms safety, security and sustainability challenges into opportunities for customers in more than 110 countries. UL Solutions delivers testing, inspection and certification services, together with software products and advisory offerings, that support our customers' product innovation and business growth. The UL Mark serves a

      5/20/25 6:32:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. Reports Strong First Quarter 2025 Results

      First Quarter 2025 (Comparisons to First Quarter 2024 unless otherwise noted)1 Strong revenue growth of 5.2% to $705 million, including 7.6% organic growth Net income of $71 million increased 18.3%, Net income margin of 10.1%, expanded 110 basis points Diluted earnings per share of $0.33 increased 17.9%, Adjusted Diluted Earnings Per Share of $0.37 increased 32.1% Adjusted EBITDA of $161 million increased 22.9%, Adjusted EBITDA margin of 22.8% expanded 320 basis points UL Solutions Inc. (NYSE:ULS), a global safety science leader in independent third-party testing, inspection and certification services and related software and advisory offerings, today reported results for the firs

      5/6/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Inc. Sets Date for First Quarter 2025 Results

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it will release financial results for the first quarter 2025 before the market opens on Tuesday, May 6. Management will host a webcast and conference call that same day at 8:30 a.m. EDT (7:30 a.m. CDT) to review results. Webcast and Conference Call The conference call will be broadcast live over the Internet. Additionally, a slide presentation will accompany the conference call. To listen to the call and view the slides, please visit the Investors section of UL Solutions' website at www.ul.com. For those who are unable to listen to the live broadcast, an audio replay of the conference call will be ava

      4/22/25 7:00:00 AM ET
      $ULS
      Precision Instruments
      Health Care

    $ULS
    Leadership Updates

    Live Leadership Updates

    See more
    • UL Solutions Inc. Names New Chief Legal Officer

      UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it appointed Scott D'Angelo as executive vice president and chief legal officer, effective April 21, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250311928632/en/UL Solutions names Scott D'Angelo as executive vice president and chief legal officer (Photo: Business Wire) D'Angelo's appointment fills a vacant role and he joins the company's executive leadership team, reporting to President and CEO Jennifer Scanlon. D'Angelo will oversee the legal, brand integrity, ethics and compliance functions. He most recently served as vice presiden

      3/11/25 9:15:00 AM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Names Chief Business Operations and Innovation Officer

      Alex Dadakis to join UL Solutions leadership team in newly created role UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced it appointed Alex Dadakis as Executive Vice President, Chief Business Operations and Innovation Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205299962/en/UL Solutions announced the appointment of Alex Dadakis as Executive Vice President, Chief Business Operations and Innovation Officer, effective Jan. 27, 2025. (Photo: Business Wire) Dadakis, who most recently served as Senior Vice President, Global Head of Strategy and Corporate Development at Germany-ba

      12/5/24 4:15:00 PM ET
      $ULS
      Precision Instruments
      Health Care
    • UL Solutions Acquires Germany-Based Battery Testing and Simulation Company BatterieIngenieure

      Deal deepens UL Solutions' global expertise in battery performance testing and expands our global EV battery testing footprint. UL Solutions Inc. (NYSE:ULS), a global leader in applied safety science, today announced our acquisition of BatterieIngenieure GmbH, a battery testing company based in Aachen, Germany, with expertise in specialized performance testing of cell, small modules and battery systems used in electric vehicles and other applications. The acquisition augments UL Solutions' global battery testing footprint with a laboratory in Europe. BatterieIngenieure provides comprehensive testing, simulation and failure analysis of battery technologies, with distinctive expertise in

      5/22/24 8:30:00 AM ET
      $ULS
      Precision Instruments
      Health Care